Twitter Feed: JAMA Health Forum
This cross-sectional study uses US county-level pharmacy claims data to examine the association of selected state policies with rates of buprenorphine...
-
Meaningful changes in access to #buprenorphine may be achieved through greater attention to professional education and clinician knowledge, according to this cross-sectional study. https://t.co/yDc2TliNri @andrakabasia, c_m_andrews, AJ_Gordon - view on twitter
More coverage:
#buprenorphine
This secondary analysis of a randomized clinical trial aims to determine the effect of eliminating out-of-pocket medication fees on total health care costs across...
-
This secondary analysis of a randomized controlled trial of primary care patients suggests that eliminating out-of-pocket medication costs for patients could reduce overall costs of health care. https://t.co/uQlDt77OF9 @AndrewDPinto - view on twitter
This cross-sectional study uses US county-level pharmacy claims data to examine the association of selected state policies with rates of buprenorphine...
-
Meaningful changes in access to #buprenorphine may be achieved through greater attention to professional education and clinician knowledge, according to this cross-sectional study. https://t.co/Edw3vMMeVT @andrakabasia, c_m_andrews, AJ_Gordon - view on twitter
More coverage:
#buprenorphine
This secondary analysis of a randomized clinical trial aims to determine the effect of eliminating out-of-pocket medication fees on total health care costs across...
-
This secondary analysis of a randomized controlled trial of primary care patients suggests that eliminating out-of-pocket medication costs for patients could reduce overall costs of health care. https://t.co/oHwGfbvHke @AndrewDPinto - view on twitter
This cohort study investigates out-of-pocket spending for ultra-expensive drugs in the Medicare Part D program vs commercial insurance from 2013 through...
Medicare #PartD beneficiaries without low-income subsidies spent 2.5 times more out-of-pocket on ultra-expensive drugs compared to commercially insured patients aged 45-64 in 2019, according to this cohort study. https://t.co/wDi6mlw4Y6 @DiStefano_MJ - view on twitter